Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 5Thoracic 3Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Breast 2Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × WW Domain-Containing Oxidoreductase × Thoracic × Clear all
NCT01335893 2018-02-05

Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green

University of Pennsylvania

Phase 1 Completed
10 enrolled
Thoracic

Lung Neoplasms

NCT00051974 2008-02-11

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.

Phase 2 Completed
155 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00064636 2005-06-24

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
46 enrolled
Other solid neoplasmThoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡